Hampstead Capital’s Celgene Corp CELG Stock Holding History

Hampstead Capital’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$984K	Hold	11,000	–	–	1.76%	18
2018 Q2	$874K	Sell	11,000 -7,000	-39%	-$581K	1.64%	17
2018 Q1	$1.61M	Hold	18,000	–	–	2.16%	22
2017 Q4	$1.88M	Sell	18,000 -12,000	-40%	-$1.35M	2.35%	22
2017 Q3	$4.38M	Sell	30,000 -5,000	-14%	-$681K	4.33%	5
2017 Q2	$4.54M	Sell	35,000 -5,000	-13%	-$613K	4.47%	4
2017 Q1	$4.98M	Hold	40,000	–	–	5.15%	4
2016 Q4	$4.63M	Buy	+40,000	New	+$4.45M	4.91%	4

Other funds holding CELG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hampstead Capital's CELG Position: Q3 2018 in Review

Hampstead Capital held its Celgene Corp (CELG) position steady in Q3 2018 at 11,000 shares worth $984K. The position accounts for 1.76% of the portfolio, ranked #18.

Hampstead Capital first reported a position in CELG in Q4 2016 and has held it in 8 quarters since. The position peaked at $4.98M in Q1 2017. 1,364 funds tracked by Wall St. Rank hold CELG as of Q3 2018.

Hampstead Capital held 11,000 shares of Celgene Corp worth $984K as of Q3 2018.
Hampstead Capital left its Celgene Corp share count unchanged in Q3 2018.
Celgene Corp made up 1.76% of Hampstead Capital's portfolio in Q3 2018, its #18 holding.
Hampstead Capital first reported a position in Celgene Corp in Q4 2016 and has held it in 8 quarters since.
Hampstead Capital's Celgene Corp position peaked at $4.98M in Q1 2017.
1,364 funds tracked by Wall St. Rank held Celgene Corp as of Q3 2018.

Based on Hampstead Capital's 13F filing for Q3 2018, filed 14 Nov 2018.